Analysis of the development trend of diabetes drug industry
Diabetes mellitus is a metabolic disorder caused by insufficient insulin secretion in the body and a decrease in insulin sensitivity of target tissue cells. According to the lack of insulin in the body, and the damage, diabetes is divided into: type I diabetes, type 2 diabetes, gestational diabetes and other types of diabetes. Among them, type I diabetes accounted for 5%, type II diabetes accounted for 90%, gestational diabetes accounted for 4%, and other diabetes accounted for 1%.
At the same time, the awareness rate and treatment rate of diabetes are also growing. According to the China Diabetes Prevention Guide (2017 edition), the awareness rate and treatment rate of type 2 diabetes in 2013 were 36.5% and 32.2%, respectively. Acarbose is a second-line treatment of oral drugs for type 2 diabetes, and the increase in awareness rate and treatment rate will lead to an increase in demand.
The number of diabetic patients in China
2016-2020 Chinese Diabetes Treatment Rate
Diabetes drug industry market size
According to the data from the Prospective Industry Research Institute's "Diagnostic and Pharmaceutical Demands and Investment Forecast Analysis Report", the market size of China's diabetes drug industry reached 23.7 billion yuan in 2016, and the market size reached 36.4 billion yuan in 2017, by 2018. The market size of China's diabetes drug industry will reach 29.2 billion yuan. It is expected that the market size of China's diabetes drug industry will reach 43.7 billion yuan in 2022. In the next few years, the market size of China's diabetes drug industry will continue to grow.
Forecast of market size of diabetes drug industry in China from 2016 to 2022
According to the distribution of diabetes patients, the urban prevalence rate and the number of patients are slightly higher than that of rural areas, while the rural prevalence rate is higher than that of cities. As a result, the demand for acarbose in the primary hospitals has grown more rapidly.
Acarbose is an oral hypoglycemic agent whose mechanism of action is to compete with oligosaccharides in the upper part of the small intestine and reversibly bind to α-glucosidase, so that the absorption of intestinal glucose is slowed down, thereby alleviating postprandial hyperglycemia. Acarbose can be used in combination with other oral hypoglycemic agents or insulin for insulin-dependent or non-insulin-dependent diabetes.
Since insulin needs to be used for a long time or even for life, product prices are an important factor in capturing the domestic insulin market. At present, for diabetic patients with mild disease, the amount of insulin used is 0.4-0.5 IU/kg; for diabetic patients with severe disease, the amount of insulin used is 0.5-0.8 IU/kg.
DPP-4 inhibitors achieved sales of 281 million yuan in the domestic market in 2017, and the annual growth rate remained above 30%.
In 2016, China's public medical institutions terminal oral hypoglycemic drugs TOP20 list, DPP-4 inhibitor drugs sitagliptin, saxagliptin, vildagliptin, linagliptin in the 12th, 16th, 18th 20, of which the sales of sitagliptin and saxagliptin exceeded 100 million yuan, and the growth rate in 2016 exceeded 20%. After Leggetin was approved to enter China in 2013, the last period was short but increased. It is booming, with a growth rate of 195.11% in 2016, which is the fastest growth of the top 20.
DPP-4 unilateral varieties are included in the 2017 national new medical insurance catalogue. With the improvement of doctors and patients' awareness of DPP-4 products, HD118 has broad prospects in the domestic diabetes market. We expect HD118 to be listed in 2020 and is expected to bring stable cash flow to the company after its launch.
In the short term, recombinant human insulin will continue to replace animal insulin; 400U/10ML×1 and 300U/3ML×1 are still the mainstream specifications for insulin; intermediate-acting insulin is still the most popular. In the long run, non-injectable insulin will replace the traditional injection form. Many patients have their eyes filled with needles due to long-term self-injection of insulin, but the emergence of inhaled insulin will make these pains a thing of the past.
The kelp soup is very convenient to eat .
Select the tender parts of the kelp, the delicious soup comes from the deep sea. After opening the paper cups, it can be soaked in boiling water for a minute, which is delicious and nutritious. Rich in nutrients needed by the human body,It can be all kinds of people, especially teenagers and young women,.It's good for health and beauty.
Kelp Soup,Kelp Broth,Wakame Seaweed Soup,Vegetarian Seaweed Soup
Shandong Haizhibao Ocean Science and Technology Co.,Ltd. , https://www.haizhibaoseafood.com